Stealthyx Therapeutics

Stealthyx Therapeutics is a pre-clinical stage biotechnology company focused on developing a proprietary platform for engineered extracellular vesicles (EVs), commonly known as exosomes. The company's technology utilizes synthetic biology to "program" the surface of exosomes, enhancing their ability to evade immune system clearance and improving the precision of therapeutic delivery to target cells. By creating "stealthy" vesicles, Stealthyx aims to overcome the pharmacokinetic limitations of traditional biologics and first-generation exosome therapies. Their primary therapeutic focus is in oncology, where they are developing treatments for solid tumors that are currently difficult to target with existing modalities. The platform is designed to be modular, allowing for the delivery of various payloads including proteins and nucleic acids. Stealthyx is a spin-out from Northwestern University, leveraging research from the Leonard Lab to advance next-generation precision medicines.